Jardiance achieves regulatory clearance


The FDA approves Boehringer Ingelheim and Eli Lilly's (LLY -1.3%) Jardiance (empagliflozin) as a treatment for glycemic control in addition to diet and exercise in adults with type 2 diabetes.

Empagliflozin is a sodium glucose co-transporter 2 inhibitor. It blocks the reabsorption of glucose by the kidney thereby increasing glucose excretion and lowering the level of glucose in the blood.

Diabetes-related tickers: (MNKD -3.3%) (MRK -0.6%)(SNY +1%)(NVO -2.6%)(GSK -1.4%)(MDT -0.8%)

From other sites
Comments (2)
  • Wall Street Sleuth
    , contributor
    Comments (100) | Send Message
     
    Is this supposed to hurt MNKD?
    1 Aug 2014, 03:04 PM Reply Like
  • Wall Street Sleuth
    , contributor
    Comments (100) | Send Message
     
    Three things hate to do: exercise, diet, and jab themselves. Does this sound like a threat to MNKD?
    1 Aug 2014, 06:24 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs